Filing Details

Accession Number:
0001652917-16-000011
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-05-19 16:26:35
Reporting Period:
2016-05-17
Filing Date:
2016-05-19
Accepted Time:
2016-05-19 16:26:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1411984 P Daniel Plew Van 777 Old Saw Mill River Road
Tarrytown NY 10591
Evp & General Mgr Industrial O No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-05-17 9,460 $30.63 11,381 No 4 M Direct
Common Stock Disposition 2016-05-17 746 $388.14 10,635 No 4 F Direct
Common Stock Disposition 2016-05-17 4,301 $388.14 6,334 No 4 F Direct
Common Stock Disposition 2016-05-18 4,413 $385.77 1,921 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2016-05-17 9,460 $0.00 9,460 $30.63
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
32,735 2020-12-14 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 18,705 Indirect by GRAT
Common Stock 1,444 Indirect By 401(k) Plan
Footnotes
  1. Represents volume-weighted average price of sales of 4,413 shares of Company stock on May 18, 2016 at prices ranging from $385.66 to $385.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 18, 2016 at each separate price.
  2. The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.